Article

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin

The Royal Marsden NHS Foundation Trust, Londinium, England, United Kingdom
Cancer Research (Impact Factor: 9.28). 05/2007; 67(7):3239-53. DOI: 10.1158/0008-5472.CAN-06-2968
Source: PubMed

ABSTRACT The promising antitumor activity of 17-allylamino-17-demethoxygeldanamycin (17AAG) results from inhibition of the molecular chaperone heat shock protein 90 (HSP90) and subsequent degradation of multiple oncogenic client proteins. Gene expression microarray and proteomic analysis were used to profile molecular changes in the A2780 human ovarian cancer cell line treated with 17AAG. Comparison of results with an inactive analogue and an alternative HSP90 inhibitor radicicol indicated that increased expression of HSP72, HSC70, HSP27, HSP47, and HSP90beta at the mRNA level were on-target effects of 17AAG. HSP27 protein levels were increased in tumor biopsies following treatment of patients with 17AAG. A group of MYC-regulated mRNAs was decreased by 17AAG. Of particular interest and novelty were changes in expression of chromatin-associated proteins. Expression of the heterochromatin protein 1 was increased, and expression of the histone acetyltransferase 1 and the histone arginine methyltransferase PRMT5 was decreased by 17AAG. PRMT5 was shown to be a novel HSP90-binding partner and potential client protein. Cellular protein acetylation was reduced by 17AAG, which was shown to have an antagonistic interaction on cell proliferation with the histone deacetylase inhibitor trichostatin A. This mRNA and protein expression analysis has provided new insights into the complex molecular pharmacology of 17AAG and suggested new genes and proteins that may be involved in response to the drug or be potential biomarkers of drug action.

Full-text

Available from: Paul Andrew Clarke, Jan 09, 2014
0 Followers
 · 
88 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cisplatin continues to be one of the cornerstone drugs in modern chemotherapy thus playing an important role among cytotoxic agents in the treatment of epithelial malignancies. Cisplatin damages, indiscriminately, cancerous and normal tissue. Its severe side effects arise from induction of apoptosis in various cell types in normal tissue in treated patients especially in peripheral nerves, renal tubules, bone marrow and gastrointestinal tract. Apoptosis may arise from the modulation of a number of signaling pathways by cisplatin including the mitochondrial pathway, the DNA damage signaling, stress-related signals, the ERK pathway and others. Patented platform technologies have been used for the liposomal encapsulation of cisplatin (Lipoplatin™) into tumor targeted 110-nm in diameter nanoparticles. Based on the molecular mechanisms of cisplatin including active import / export across the cell membrane, signaling pathway modulation and DNA damage an attempt is made to speculate on the molecular mechanisms of Lipoplatin™. The advantage of Lipoplatin™ over cisplatin is suggested to result from the ability of Lipoplatin™ to target primary tumors and metastases using the permeability of the vasculature of the growing tumor for its preferential extravasation and to cause a greater damage to tumor tissue compared to normal tissue as demonstrated in human studies. The nanoparticles are then avidly taken up by the tumors either via phagocytosis or by direct fusion with the cell membrane. The two mechanisms result to an overall 10 to 400-fold higher intracellular uptake of total platinum in tumor cells compared to cells in normal tissue in human studies. Animal studies shown here suggest that genes wrapped up in Lipoplatin™ shells target not only the tumors after systemic delivery but also their vasculature and result in the expression of a functional gene product after crossing the cell membrane barrier. It is being inferred that Lipoplatin™ is endowed with the properties of cisplatin plus the ability of its nanoparticles to target and kill endothelial cells of tumor vasculature suggesting that this drug has two properties, that of a chemotherapy drug and that of an antiangiogenesis agent, combined together. Lipoplatin™ is finishing successfully two non-inferiority phase III clinical trials as first line treatment against non-small cell lung cancer (NSCLC) and has received the orphan drug designation by EMEA against pancreatic cancer.
    Cancer therapy 01/2007; 5:349-376.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Telomerase confers cellular immortality by elongating telomeres, thereby circumventing the Hayflick limit. Extended-life-span cells have been generated by transfection with the human telomerase reverse transcriptase (hTERT) gene. hTERT transfected cell lines may be of outstanding interest to monitor the effect of drugs targeting the telomerase activity. The incidence of hTERT gene transfection at the proteome level is a prerequisite to that purpose. The effect of the transfection has been studied on the proteome of human fibroblast (WI38). Cytosolic and nuclear fractions of WI38 cells, empty vector transfected WI38 (WI38-HPV) and hTERT WI38 cells were submitted to a 2D-DIGE (Two-Dimensional Differential In-Gel Electrophoresis) analysis. Only spots that had a similar abundance in WI38 and WI38-HPV, but were differentially expressed in WI38 hTERT were selected for MS identification. This method directly points to the proteins linked with the hTERT expression. Number of false positive differentially expressed proteins has been excluded by using control WI38-HPV cells. The proteome alteration induced by hTERT WI38 transfection should be taken into account in subsequent use of the cell line for anti-telomerase drugs evaluation. 2D-DIGE experiment shows that 57 spots out of 2246 are significantly differentially expressed in the cytosolic fraction due to hTERT transfection, and 38 were confidently identified. In the nuclear fraction, 44 spots out of 2172 were selected in the differential proteome analysis, and 14 were identified. The results show that, in addition to elongating telomeres, hTERT gene transfection has other physiological roles, among which an enhanced ER capacity and a potent cell protection against apoptosis. We show that the methodology reduces the complexity of the proteome analysis and highlights proteins implicated in other processes than telomere elongation. hTERT induced proteome changes suggest that telomerase expression enhances natural cell repair mechanisms and stress resistance probably required for long term resistance of immortalized cells. Thus, hTERT transfected cells can not be only consider as an immortal equivalent to parental cells but also as cells which are over-resistant to stresses. These findings are the prerequisite for any larger proteomics aiming to evaluate anti-telomerase drugs proteome alteration and thus therapeutics induced cell reactions.
    Proteome Science 02/2008; 6:12. DOI:10.1186/1477-5956-6-12 · 1.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epigenetics is essentially a phenotypical change in gene expression without any alteration of the DNA sequence; the emergence of epigenetics in cancer research and mainstream oncology is fueling new hope. However, it is not yet known whether this knowledge will translate to improved clinical management of ovarian cancer. In this malignancy, women are still undergoing chemotherapy similar to what was approved in 1978, which to this day represents one of the biggest breakthroughs for treating ovarian cancer. Although liquid tumors are benefiting from epigenetically related therapies, solid tumors like ovarian cancer are not (yet?). Herein, we will review the science of molecular epigenetics, especially DNA methylation, histone modifications and microRNA, but also include transcription factors since they, too, are important in ovarian cancer. Pre-clinical and clinical research on the role of epigenetic modifications is also summarized. Unfortunately, ovarian cancer remains an idiopathic disease, for the most part, and there are many areas of patient management, which could benefit from improved technology. This review will also highlight the evidence suggesting that epigenetics may have pre-clinical utility in pharmacology and clinical applications for prognosis and diagnosis. Finally, drugs currently in clinical trials (i.e., histone deacetylase inhibitors) are discussed along with the promise for epigenetics in the exploitation of chemoresistance. Whether epigenetics will ultimately be the answer to better management in ovarian cancer is currently unknown; but we hope so in the future.
    Frontiers in Oncology 04/2014; 4:71. DOI:10.3389/fonc.2014.00071